onartuzumab [MetMAb]

DRUG2 trials

Sponsors

Genentech, Inc., Hoffmann-La Roche

Conditions

Colorectal CancerNon-Small Cell Lung Cancer

Phase 2

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

CompletedNCT01418222

Genentech, Inc.Colorectal Cancer

Start: 2011-09-14End: 2013-03-18Updated: 2017-05-30

Phase 3

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

CompletedNCT02031744

Hoffmann-La RocheNon-Small Cell Lung Cancer

Start: 2014-01-22End: 2016-01-06Target: 530Updated: 2017-03-14

Related Papers

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

2017-02-1648 citations

A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2015-01-207 citations